New eye drops to treat blindness caused by sulfur mustard exposure
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
This study is testing a new eye drop treatment made from four safe, approved medicines to help people who have vision problems from exposure to sulfur mustard gas, and it aims to see how well these drops can heal eye injuries and improve vision.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10894712 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for blindness caused by sulfur mustard gas, a harmful chemical agent. The approach involves using Turbo Eye Drops, which contain four FDA-approved drugs that work together to reduce inflammation and promote healing in the eye. The research aims to demonstrate the effectiveness of these eye drops in treating both immediate and delayed eye injuries caused by sulfur mustard. Patients will be monitored for improvements in their ocular health and any side effects during the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced eye injuries from sulfur mustard gas exposure, particularly those showing symptoms of Mustard Gas Keratopathy.
Not a fit: Patients who have not been exposed to sulfur mustard or do not exhibit symptoms related to Mustard Gas Keratopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from severe eye injuries and potential blindness due to sulfur mustard exposure.
How similar studies have performed: Previous studies have shown promising results with similar approaches in treating ocular injuries, but this specific treatment is novel and has not been widely tested.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Mohan, Rajiv Ravindra — University of Missouri-Columbia
- Study coordinator: Mohan, Rajiv Ravindra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.